Cancer Treatment Reviews

Article	Citations
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook	544
Review of precision cancer medicine: Evolution of the treatment paradigm	323
Immunotherapy for pancreatic cancer: A 2020 update	257
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis	184
MYC as a target for cancer treatment	168
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target	166
KRAS: From undruggable to a druggable Cancer Target	130
How did lomustine become standard of care in recurrent glioblastoma?	119
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies	111
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma	89
The role of autophagy in resistance to targeted therapies	88
Microsatellite instability in Gastric Cancer: Between lights and shadows	88
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer	87
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality	85
BAP1: Not just a BRCA1-associated protein	84
Targeting FGFR inhibition in cholangiocarcinoma	84
MEK inhibitor resistance mechanisms and recent developments in combination trials	83
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal	81
Treatment landscape of metastatic pancreatic cancer	81
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures	80
Cancer and COVID-19: Unmasking their ties	76
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer	75
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins	74
Global challenges and policy solutions in breast cancer control	74
Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities	72

HER2-positive advanced breast cancer treatment in 2020	70
Challenges in the treatment of gastric cancer in the older patient	70
Targeting ARID1A mutations in cancer	65
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	65
The role of exosomes in metastasis and progression of melanoma	63
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	60
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	59
Evolving role of regorafenib for the treatment of advanced cancers	59
SARS-CoV-2 and cancer: Are they really partners in crime?	58
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application	56
NRAS mutant melanoma: Towards better therapies	56
Immunotherapy in non-small cell lung cancer harbouring driver mutations	55
Parathyroid cancer: An update	52
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping	51
Melanoma brain metastases – Interdisciplinary management recommendations 2020	50
Thymic epithelial tumors: From biology to treatment	47
Targeting brain metastases in breast cancer	46
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis	45
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials	45
Targeting HER2 heterogeneity in breast cancer	44
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives	44
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic	43
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	43
Roadmap to cure multiple myeloma	43
The force of HER2 – A druggable target in NSCLC?	42
Liquid biopsy in lymphoma: Molecular methods and clinical applications	41
Turning tumors from cold to inflamed to improve immunotherapy response	41
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis	41
Cabozantinib: An evolving therapy for hepatocellular carcinoma	40
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis	40
Treatment strategies for patients with diffuse large B-cell lymphoma	40
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression	39
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	38
A basic review on systemic treatment options in WHO grade II-III gliomas	38
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data	38
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond	37
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors	37
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer	36
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials	36
Neurological complications of cancer immunotherapy	34
Precision medicine in breast cancer: From clinical trials to clinical practice	34
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives	34
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone	33
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer	33
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?	33
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis	33
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives	32
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	31
A review of retroperitoneal liposarcoma genomics	31
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities	30

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review	30
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus	30
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice	30
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer	29
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)	29
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis	29
The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence	29
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes	28
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis	28
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges	28
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities	28
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	28
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	28
Current management of stage IV nasopharyngeal carcinoma without distant metastasis	28
Accelerating drug development in breast cancer: New frontiers for ER inhibition	28
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials	27
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)	27
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification	27
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications	27
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer	27
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future	27
The promise of bispecific antibodies: Clinical applications and challenges	27
Immunotherapy in cervix cancer	27
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era	26
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers	25
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	25
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors	25
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer	25
Seroprevalence of SARS-CoV-2–specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data	24
The current clinical landscape of personalized cancer vaccines	23
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations	23
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation	23
Prognostic factors in patients with oligometastatic breast cancer – A systematic review	23
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	22
Newly diagnosed ovarian cancer: Which first-line treatment?	22
Clinical trial data of Anti–PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review	21
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	21
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	21
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	21
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?	21
Recent advancements of antiangiogenic combination therapies in ovarian cancer	20
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment	20
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis	20
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours	20
Clinical development of IDH1 inhibitors for cancer therapy	20
Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000–19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4	20
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias	20
Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis	19
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer	19
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immorta	19
The landscape of new drugs in extranodal NK/T-cell lymphoma	19
Organoid models in gynaecological oncology research	19
Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis	19
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	19
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer	19
Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies	19
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences	18
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon	18
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	18
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	18
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC	17
The use of immunotherapy in older patients with advanced non-small cell lung cancer	17
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis	17
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)	17
Current management and future perspectives of penile cancer: An updated review	17
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)	17
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data	17
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor	17
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	17
Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature	16
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy	16
Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN)	16
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives	16
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group	16
De-escalation of axillary irradiation for early breast cancer – Has the time come?	16
Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives	16
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants	16
Basket trials: From tumour gnostic to tumour agnostic drug development	15
The evolving landscape of antibody-drug conjugates in gynecologic cancers	15
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies	15

A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research	15
Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review	15
Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery	15
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge	15
Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics	15
Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?	15
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines	15
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy	15
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer	14
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics	14
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality	14
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	14
Checkpoint inhibitors in metastatic papillary renal cell carcinoma	14
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care	14
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis – A review	14
Rethinking breast cancer follow-up based on individual risk and recurrence management	14
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care	14
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer	14
Targeting NaPi2b in ovarian cancer	14
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	14
Treatment of venous thromboembolism in cancer patients: The dark side of the moon	13
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news	13
Beyond HER2: Targeting the ErbB receptor family in breast cancer	13
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies	13
The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 ×5 Gy) in rectal cancer - are we too eager for surgery?	13
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review	13
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options	13
Toxicities following CAR-T therapy for hematological malignancies	13
Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis	13
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies	13
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis	13
Systematic review of the CUP trials characteristics and perspectives for next-generation studies	12
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review	12
Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis	12
Immunotherapy in advanced anal cancer: Is the beginning of a new era?	12
A comprehensive overview of promising biomarkers in stage II colorectal cancer	12
Systematic review of fetal and placental metastases among pregnant patients with cancer	12
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers	11
Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer	11
Current state of play for HPV-positive oropharyngeal cancers	11
Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review	11
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?	11
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors	11
Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review	11
Advances in immunotherapy for MMR proficient colorectal cancer	11
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?	11
HER2 targeted therapy in colorectal cancer: New horizons	11
Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis	11
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts	10
Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities	10
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis	10
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis	10
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside	10
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis	10
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of	10
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis	10
Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy	10
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage	10
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision	10
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	10
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer	10
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?	9
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence	9
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review	9
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	9
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer	9
Desmoplastic Small Round Cell Tumors: A review with focus on clinical management and therapeutic options	9
Imaging and clinical correlates with regorafenib in metastatic colorectal cancer	9
Is DNA repair a potential target for effective therapies against malignant mesothelioma?	9
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations	9
The microbiota and radiotherapy for head and neck cancer: What should clinical oncologists know?	8
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors	8
Drug dosing in cancer patients with decreased kidney function: A practical approach	8
Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours	8
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review	8
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges	8
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination	8
Novel targets for immune-checkpoint inhibition in cancer	8
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	8
Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review	8
Association of immune checkpoint inhibitors with respiratory infections: A review	8
Targeting complex, adaptive responses in melanoma therapy	8
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives	8
Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review	8